Abstract:High-throughput drug screening is crucial for advancing healthcare through drug discovery. However, a significant limitation arises from available in vitro models using conventional 2D cell culture, which lack the proper phenotypes and architectures observed in 3D tissues. Recent advancements in stem cell biology have facilitated the generation of organoids—3D tissue constructs that mimic human organs in vitro. Kidney organoids, derived from human pluripotent stem cells, represent a significant breakthrough in disease representation. They encompass major kidney cell types organized within distinct nephron segments, surrounded by stroma and endothelial cells. This tissue allows for the assessment of structural alterations such as nephron loss, a characteristic of chronic kidney disease. Despite these advantages, the complexity of 3D structures has hindered the use of organoids for large-scale drug screening, and the drug screening pipelines utilizing these complex in vitro models are yet to be established for high-throughput screening. In this study, we address the technical limitations of kidney organoids through fully automated 3D imaging, aided by a machine-learning approach for automatic profiling of nephron segment-specific epithelial morphometry. Kidney organoids were exposed to the nephrotoxic agent cisplatin to model severe acute kidney injury. An FDA-approved drug library was tested for therapeutic and nephrotoxicity screening. The fully automated pipeline of 3D image acquisition and analysis identified nephrotoxic or therapeutic drugs during cisplatin chemotherapy. The nephrotoxic potential of these drugs aligned with previous in vivo and human reports. Additionally, Imatinib, a tyrosine kinase inhibitor used in hematological malignancies, was identified as a potential preventive therapy for cisplatin-induced kidney injury. Our proof-of-concept report demonstrates that the automated screening process, using 3D morphometric assays with kidney organoids, enables high-throughput screening for nephrotoxicity and therapeutic assessment in 3D tissue constructs.

Bioprinting of 3D Convoluted Renal Proximal Tubules on Perfusable Chips

3D Humanized Bioprinted Tubulointerstitium Model to Emulate Renal Fibrosis In Vitro

Developing a Self-Organized Tubulogenesis Model of Human Renal Proximal Tubular Epithelial Cells in Vitro.

A biomimetic kidney tubule model

A perfusable, vascularized kidney organoid-on-chip model

Three-Dimensional Printing and Bioprinting in Renal Transplantation and Regenerative Medicine: Current Perspectives

Functional Evaluation and Nephrotoxicity Assessment of Human Renal Proximal Tubule Cells on a Chip

Renal proximal tubule-on-a-chip in PDMS: fabrication, functionalization, and RPTEC:HUVEC co-culture evaluation

Grafting of 3D Bioprinting to in Vitro Drug Screening: A Review

Three-Dimensional Renal Organoids from Whole Kidney Cells: Generation, Optimization, and Potential Application in Nephrotoxicology in Vitro

Coaxial cell printing of a human glomerular model: an <i>in vitro</i> glomerular filtration barrier and its pathophysiology

Bioprinting of Novel 3D Tumor Array Chip for Drug Screening

Kidney Organoid and Microphysiological Kidney Chip Models to Accelerate Drug Development and Reduce Animal Testing

Advanced Kidney Models In Vitro Using the Established Cell Line Renal Proximal Tubular Epithelial/Telomerase Reverse Transcriptase1 for Nephrotoxicity Assays

Efficient Drug Screening and Nephrotoxicity Assessment on Co-culture Microfluidic Kidney Chip

Advancing preclinical drug evaluation through automated 3D imaging for high-throughput screening with kidney organoids

An immunocompetent human kidney on-a-chip model to study renal inflammation and immune-mediated injury

Decellularized porcine kidney-incorporated hydrogels for cell-laden bioprinting of renal cell carcinoma model

A murine ex vivo 3D kidney proximal tubule model predicts clinical drug-induced nephrotoxicity

Bioprinting a 3D Vascular Construct for Engineering a Vessel-on-a-chip

3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling.